Search News Archives
Special Offers and Promotions
Conferences | Events
Absolute Antibody Opens New Facility to Support Continued Growth of its Recombinant Antibody Technology
New UK facility significantly increases laboratory space and antibody production capacity
Absolute Antibody Ltd., specialists in antibody sequencing, engineering and recombinant expression with a vision to make recombinant antibody technology accessible to all, has announced the opening of a new facility in northeast England.
The new facility more than doubles Absolute Antibody’s laboratory space and will enable an even greater increase in its antibody production capacity, allowing the company to better service customers and accelerate the expansion of its recombinant antibody portfolio.
Since its founding in 2012, Absolute Antibody has grown rapidly. Their custom antibody sequencing, engineering and expression services are used by leading pharmaceutical, biotechnology and diagnostics companies, as well as by academic researchers worldwide. Their reagents catalogue offers more than 3,800 recombinant antibodies in new engineered formats, absolutely defined at the amino acid level to ensure batch-to-batch reproducibility.
“The new facility supports the continued growth of our company and underlines our commitment to advancing recombinant antibody technology,” said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “We are excited to leverage our increased production capacity to serve new and existing customers more efficiently, as well as significantly expand our catalogue of research-ready recombinant antibodies.”
The new facility is located at the Wilton Centre in Redcar, England, where Absolute Antibody has based its research and manufacturing since 2014. The upgraded space includes larger dedicated labs for molecular biology, automation, tissue culture and purification, as well as expanded shipping and storage areas. The new labs will also accommodate additional staff members and new robotic equipment to support company growth.
Absolute Antibody’s facility expansion comes in the same year as its merger with Boston, US-based Kerafast, Inc., a reagent company that facilitates access to unique laboratory-made research tools from 177 prominent research institutions worldwide. The merger is enabling a larger global reach for the combined company, and the new facility will help support increasing worldwide demand for recombinant antibody products and services.
About Absolute Antibody
Absolute Antibody is an Oxford, UK-based company with a vision to make recombinant antibody technology accessible to all. We offer antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalogue of recombinant antibodies, engineered into new and useful formats.